Demant Receivables 2012-2024 | WILYY

Demant receivables for the quarter ending June 30, 2024 were $0.646B, a 0.72% increase year-over-year.

  • Demant receivables for 2024 were $0.623B, a 3.66% decline from 2023.
  • Demant receivables for 2023 were $0.646B, a 6.22% increase from 2022.
  • Demant receivables for 2022 were $0.609B, a 5.17% decline from 2021.

Demant Receivables 2012-2024 | WILYY

  • Demant receivables for 2024 were $0.623B, a 3.66% decline from 2023.
  • Demant receivables for 2023 were $0.646B, a 6.22% increase from 2022.
  • Demant receivables for 2022 were $0.609B, a 5.17% decline from 2021.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$231B
Boston Scientific (BSX)$155.5B
Stryker (SYK)$147.4B
EssilorLuxottica (ESLOY)$140.8B
Medtronic (MDT)$112.8B
Lonza Group Ag (LZAGY)$47.1B
Haleon (HLN)$44.8B
GE HealthCare Technologies (GEHC)$42.1B
Agilent Technologies (A)$39B
ResMed (RMD)$34.2B
Terumo (TRUMY)$26.3B
Koninklijke Philips (PHG)$23.5B
Zimmer Biomet Holdings (ZBH)$20.6B
Insulet (PODD)$20.2B
Baxter (BAX)$17.1B
Sunny Optical Technology (SNPTF)$11.3B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$9.5B
Bio-Rad Laboratories (BIO)$8B
Lantheus Holdings (LNTH)$5.6B
Prestige Consumer Healthcare (PBH)$4.2B
ICU Medical (ICUI)$4B
Envista Holdings (NVST)$3.7B
Perrigo (PRGO)$3.4B
Haemonetics (HAE)$3.2B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.8B
LeMaitre Vascular (LMAT)$2.3B
Neogen (NEOG)$2.2B